Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

neurology

  • Home
  •  
  • neurology



  • Most Read
  • Latest Comments
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Amplia reports results from initial clinical trials of pancreatic cancer drug
    Amplia reports results from initial clinical trials of pancreatic cancer drug
    • News

  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

  • Pharmaxis welcomes leading medical researcher and healthcare investment guru as Director
    Pharmaxis welcomes leading medical researcher and healthcare investment guru as Director
    • News

  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • News

  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
    • News

    Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder

    The complexity of the human body never ceases to amaze me. So many systems need to work together to carry out seemingly simple tasks like walking, breathing and digesting. This complexity means that from time to time the convoluted web of neurons, strands of DNA and woven matrices of bone can be subject to defects. 

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.